GNI Group Ltd
Save
–
Market cap
14.76x
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy.
Similar securities
Based on sector and market capitalization
Report issue